Denali Stock Based Compensation vs Investments Analysis
DNLI Stock | USD 20.92 0.53 2.47% |
Denali Therapeutics financial indicator trend analysis is much more than just examining Denali Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Denali Therapeutics is a good investment. Please check the relationship between Denali Therapeutics Stock Based Compensation and its Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
Stock Based Compensation vs Investments
Stock Based Compensation vs Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Denali Therapeutics Stock Based Compensation account and Investments. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Denali Therapeutics' Stock Based Compensation and Investments is 0.4. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Investments in the same time period over historical financial statements of Denali Therapeutics, assuming nothing else is changed. The correlation between historical values of Denali Therapeutics' Stock Based Compensation and Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Denali Therapeutics are associated (or correlated) with its Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Investments has no effect on the direction of Stock Based Compensation i.e., Denali Therapeutics' Stock Based Compensation and Investments go up and down completely randomly.
Correlation Coefficient | 0.4 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Investments
Securities or assets acquired for generating income or appreciating in value, not used in daily operations.Most indicators from Denali Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.The current Selling General Administrative is estimated to decrease to about 54.3 M. The current Tax Provision is estimated to decrease to -6,300
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 4.6M | 14.8M | 51.5M | 54.1M | Net Interest Income | 4.6M | 14.8M | 45.0M | 47.3M |
Denali Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Denali Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Denali Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 553.2M | 1.6B | 1.4B | 1.5B | 1.2B | 932.8M | |
Other Current Liab | 20.4M | 42.5M | 47.7M | 63.8M | 61.2M | 31.3M | |
Total Current Liabilities | 45.3M | 71.7M | 378.2M | 363.9M | 78.0M | 121.8M | |
Total Stockholder Equity | 394.9M | 1.2B | 962.3M | 1.0B | 1.0B | 712.9M | |
Other Liab | 44.1M | 317.9M | 5.1M | 858K | 986.7K | 937.4K | |
Net Tangible Assets | 394.9M | 1.2B | 962.3M | 1.0B | 1.2B | 612.3M | |
Property Plant And Equipment Net | 80.7M | 73.5M | 69.6M | 74.5M | 71.6M | 52.4M | |
Net Debt | (10.6M) | (443.0M) | (234.9M) | (157.7M) | (74.9M) | (78.6M) | |
Retained Earnings | (425.6M) | (354.4M) | (645.0M) | (971.0M) | (1.1B) | (1.1B) | |
Accounts Payable | 2.6M | 1.1M | 4.8M | 2.8M | 9.5M | 10.0M | |
Cash | 79.4M | 507.1M | 293.5M | 218.0M | 127.1M | 194.5M | |
Non Current Assets Total | 123.2M | 108.6M | 506.9M | 87.9M | 89.8M | 154.9M | |
Non Currrent Assets Other | 2.7M | 2.5M | 11.9M | 11.9M | 18.1M | 19.1M | |
Other Assets | 2.7M | 2.5M | 11.9M | 13.4M | 1.0 | 0.95 | |
Cash And Short Term Investments | 415.4M | 1.5B | 865.4M | 1.3B | 1.0B | 757.9M | |
Common Stock Shares Outstanding | 95.6M | 112.7M | 121.5M | 125.5M | 137.4M | 86.7M | |
Liabilities And Stockholders Equity | 553.2M | 1.6B | 1.4B | 1.5B | 1.2B | 932.8M | |
Non Current Liabilities Total | 113.0M | 382.1M | 63.6M | 53.9M | 45.0M | 42.7M | |
Capital Surpluse | 774.2M | 818.8M | 1.5B | 1.6B | 1.8B | 1.9B | |
Other Current Assets | 14.7M | 20.3M | 30.6M | 26.8M | 26.2M | 17.6M | |
Other Stockholder Equity | 818.8M | 1.5B | 1.6B | 2.0B | 2.1B | 1.1B | |
Total Liab | 158.3M | 453.7M | 441.9M | 417.8M | 123.0M | 220.0M | |
Property Plant And Equipment Gross | 80.7M | 73.5M | 69.6M | 74.5M | 117.6M | 123.5M | |
Total Current Assets | 430.0M | 1.5B | 897.2M | 1.4B | 1.1B | 778.0M | |
Accumulated Other Comprehensive Income | 350K | (245K) | (2.5M) | (6.9M) | 643K | 675.2K | |
Common Stock | 1.3M | 1.5M | 1.5M | 1.7M | 1.7M | 1.6M | |
Property Plant Equipment | 80.7M | 40.8M | 69.6M | 74.5M | 85.7M | 44.6M | |
Short Term Investments | 335.9M | 962.6M | 571.9M | 1.1B | 907.4M | 633.8M | |
Long Term Investments | 61.3M | 147.9M | 39.9M | 32.7M | 425.4M | 0.0 | |
Non Current Liabilities Other | 467K | 471K | 379K | 382.1M | 435.9K | 414.1K | |
Net Invested Capital | 394.9M | 1.2B | 962.3M | 1.0B | 1.0B | 879.0M | |
Net Working Capital | 384.7M | 1.4B | 519.0M | 1.0B | 986.2M | 811.7M | |
Current Deferred Revenue | 18.7M | 23.5M | 320.3M | 290.1M | (46.9M) | (44.6M) | |
Capital Stock | 1.3M | 1.5M | 1.5M | 1.7M | 1.7M | 1.7M | |
Short Term Debt | 3.7M | 4.7M | 5.5M | 7.3M | 7.3M | 6.3M |
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.